比伐卢定在心血管介入治疗急性心肌梗死中的临床效果

Clinical effect of Bivalirudin in the treatment of acute myocardial infarction with cardiovascular intervention

目的探讨比伐卢定与心血管介入治疗急性心肌梗死的临床效果。方法选取2016年8月~2017年8月我院收治的100例急性心肌梗死患者作为研究对象,采取双盲法将其分为对照组和实验组,每组各50例。对照组患者采取普通肝素来进行抗凝治疗,实验组患者采取比伐卢定来进行抗凝治疗。比较分析两组患者的手术资料、TIMI血流改善情况以及术后主要不良心血管事件(MACE)出血发生率。结果两组患者的手术资料比较,差异无统计学意义(P>0.05);实验组患者的TIMI血流分级情况优于对照组患者,差异有统计学意义(P<0.05);实验组患者术后30 d内MACE以及出血的发生率低于对照组,差异有统计学意义(P<0.05)。结论急性心肌梗死患者接受比伐卢定联合心血管介入的治疗方式,取得了显著的治疗效果,安全性也更高,值得更加广泛地应用于临床。

Objective To investigate the clinical effect of Bivalirudin in the treatment of acute myocardial infarction with cardiovascular intervention. Methods A total of 100 patients with acute myocardial infarction admitted to our hos- pital from August 2016 to August 2017 were selected as the study subjects. The patients were divided into control group and experimental group. There were 50 patients in each group. Patients received common heparin for anticoagu- lant therapy, meanwhile patients in the experimental group took bivalirudin for anticoagulant therapy. The surgical data, TIMI flow improvement, and postoperative MACE bleeding were compared between the two groups. Results There was no significant difference in the surgical data between the two groups （P〉0.05）. The TIMI blood flow improvement in the experimental group was better than that in the control group, the difference was statistically significant （P〈0.05）. The incidence of MACE and bleeding within 30 days after surgery were lower than those in the control group, and the dif- ferences were statistically significant （P〈0.05）. Conclusion The treatment of patients with acute myocardial infarction who received Bivalirudin combined with cardiovascular intervention has achieved significant therapeutic effect, with high safety, and it is worthy of being more widely used in clinical practice.